TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38046981

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 µg administered via dry powder inhaler, single and multiple (twice daily) doses.
Number of subjects: 20
Study: 38047142

Group type: EXPERIMENTAL
Intervention: Methadone (0.10 mg/kg to 0.20 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 38047249

Group type: EXPERIMENTAL
Intervention: SNG100 cream (hydrocortisone 1% in a cream base with sulphated polysaccharide), applied twice daily for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% cream, applied once daily for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream, applied twice daily for 14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SNG100 cream
Number of subjects: 60
Study: 38047365

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Shared Decision-Making Model (CBSDM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 18
Study: 38047535

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Biopsy Calcitonin Measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38047967

Group type: EXPERIMENTAL
Intervention: Self-reported sleep diary
Number of subjects: 120
Study: 38048045

Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE at a dose of 7.4 GBq (200 mCi) every eight weeks for four cycles
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Number of subjects: 14
Study: 38048133

Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretic
Number of subjects: 32804

Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB)
Number of subjects: 32804

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitor
Number of subjects: 32804
Study: 38048134

Group type: EXPERIMENTAL
Intervention: Cilostazol, 50 mg twice daily for up to 96 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo, 1 tablet twice daily for up to 96 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 38048145

Group type: EXPERIMENTAL
Intervention: GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare Metal Stenting (BMS)
Number of subjects: 0
Study: 38048147

Group type: EXPERIMENTAL
Intervention: MyBP program (automated bidirectional text messaging for home blood pressure monitoring)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MyBP program
Number of subjects: 17
Study: 38048188

Group type: EXPERIMENTAL
Intervention: Intravenous levothyroxine (30 μg per hour for a minimum of 12 hours)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Intravenous levothyroxine
Number of subjects: 838
Study: 38048354

Group type: EXPERIMENTAL
Intervention: CT-based regional dcCL scales
Number of subjects: 4062

Group type: EXPERIMENTAL
Intervention: CT-based regional dcCL scales with mCERAD cutoff of 1.5
Number of subjects: 4062

Group type: EXPERIMENTAL
Intervention: CT-based regional dcCL scales with mCERAD cutoff of 0.5
Number of subjects: 4062
Study: 38048391

Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd)
Number of subjects: 0
Study: 38048480

Group type: EXPERIMENTAL
Intervention: Web-based mindful self-compassion for teens (MSC-T) intervention
Number of subjects: 141

Group type: COMPARATOR
Intervention: Waitlist control group (standard of care)
Number of subjects: 141
Study: 38048552

Group type: EXPERIMENTAL
Intervention: MRD negativity
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Risk factors (ISS 3, ≥0.01% CTCs, late MRD negativity)
Number of subjects: 267
Study: 38048557

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide
Number of subjects: 306

Group type: COMPARATOR
Intervention: Lenalidomide alone
Number of subjects: 306
Study: 38048573

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 12512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12512
Study: 38048694

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab monotherapy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 293
Study: 38048757

Group type: EXPERIMENTAL
Intervention: Respiratory support (oxygen only, CPAP, or mechanical ventilation) in term infants
Number of subjects: 205977

Group type: COMPARATOR
Intervention: Respiratory support (oxygen only, CPAP, or mechanical ventilation) in preterm infants
Number of subjects: 205977
Study: 38048786

Group type: EXPERIMENTAL
Intervention: Imetelstat 7.5 mg/kg administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 38048793

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus standard therapy (cisplatin 50 mg/m2)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard therapy (cisplatin 50 mg/m2)
Number of subjects: 410
Study: 38048799

Group type: EXPERIMENTAL
Intervention: Vitamin D (oral dose of 14,000 IU/week)
Number of subjects: 8348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8348
Study: 38048802

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy with camrelizumab (one cycle of priming doublet chemotherapy at 75-80 mg/m2)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy with camrelizumab
Number of subjects: 85
Study: 38048882

Group type: EXPERIMENTAL
Intervention: Re-POT technique
Number of subjects: 500
Study: 38048986

Group type: EXPERIMENTAL
Intervention: Clearsight™ system (non-invasive monitoring)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: PI ≤ 0.85%
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CRT > 4 s
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Presence of hand edema
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cardiac arrhythmia
Number of subjects: 152
Study: 38049159

Group type: EXPERIMENTAL
Intervention: Falls Decision Rule (no head CT required)
Number of subjects: 4308

Group type: EXPERIMENTAL
Intervention: Diagnosis of clinically important intracranial bleeding
Number of subjects: 4308
Study: 38049197

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 0.5 mg/kg intravenously (IV) twice daily (b.i.d)
Number of subjects: 6
Study: 38049523

Group type: EXPERIMENTAL
Intervention: Intracranial injection of poly(I:C)
Number of subjects: 27
Study: 38049586

Group type: EXPERIMENTAL
Intervention: CD138-low/CD27-neg immunophenotypic profile
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: CD138-low/CD27-neg pattern
Number of subjects: 1389
Study: 38049620

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation within the central lateral (CL) nucleus of the thalamus and the associated medial dorsal tegmental (CL/DTTm) tract.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation within the CL/DTTm tract (surgery with electrode placement guided by imaging).
Number of subjects: 6
Study: 38049622

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 399

Group type: COMPARATOR
Intervention: Enzalutamide alone (placebo group)
Number of subjects: 399
Study: 38049621

Group type: COMPARATOR
Intervention: Bivalent vaccine
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Nonavalent vaccine
Number of subjects: 2275

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2275
Study: 38049713

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional fluid therapy
Number of subjects: 100
Study: 38049783

Group type: EXPERIMENTAL
Intervention: DNA-methylation profiling on liquid biopsies
Number of subjects: 75

Group type: COMPARATOR
Intervention: Chemoradiation therapy (CRT)
Number of subjects: 75
Study: 38049806

Group type: EXPERIMENTAL
Intervention: High-density transcranial direct current stimulation (HD-tDCS) for 20 minutes at up to 0.63 mA, applied over ipsilesional DLPFC, contralesional cerebellum, or combined DLPFC + contralesional cerebellum.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS intervention.
Number of subjects: 0
Study: 38049905

Group type: EXPERIMENTAL
Intervention: Multidimensional physiotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 70
Study: 38049955

Group type: EXPERIMENTAL
Intervention: EDV add-on treatment to TAU (intravenous infusion with 30 mg of EDV twice per day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: NGF add-on treatment to TAU (intramuscular injection of 20 μg of NGF per day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Treatment as usual (TAU: a combination of intramuscular injections of thiamine, intravenous infusions of other B vitamins with vitamin C and oral medication with vitamin E per day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: EDV add-on treatment to TAU
Number of subjects: 122
Study: 38050037

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once a week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38050056

Group type: EXPERIMENTAL
Intervention: Ringer's lactate (RL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 52
Study: 38050066

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate and taurursodiol (PB and TURSO)
Number of subjects: 0
Study: 38050090

Group type: EXPERIMENTAL
Intervention: NeVa device
Number of subjects: 139
Study: 38050127

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38050181

Group type: EXPERIMENTAL
Intervention: Sweet-flavoured cigarillos
Number of subjects: 0
Study: 38050187

Group type: EXPERIMENTAL
Intervention: Symptom screening programme for CTEPH detection
Number of subjects: 646

Group type: COMPARATOR
Intervention: Routine care (before symptom screening protocol)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Echocardiographic probability of pulmonary hypertension (PH) after symptom screening
Number of subjects: 646
Study: 38050584

Group type: EXPERIMENTAL
Intervention: Mindful Steps intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 19
Study: 38050693

Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic-naive)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic-experienced)
Number of subjects: 489
Study: 38050737

Group type: EXPERIMENTAL
Intervention: CA19-9-normal subgroup (≤37 U/mL)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: CA19-9-high subgroup (>37 U/mL)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Glucose control in pancreatic cancer animal models
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Glucose control in clinical trial (NCT05306028)
Number of subjects: 1558
Study: 38050854

Group type: EXPERIMENTAL
Intervention: Corticosteroids given orally
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study: 38051008

Group type: EXPERIMENTAL
Intervention: EnhanceFitness (EF) physical activity intervention, 12-week duration, thrice weekly classes
Number of subjects: 323

Group type: COMPARATOR
Intervention: Delayed group (wait-list control)
Number of subjects: 323
Study: 38051029

Group type: EXPERIMENTAL
Intervention: 3T MRI with T2 and diffusion-weighted imaging (DWI)
Number of subjects: 50
Study: 38051146

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 0
Study: 38051184

Group type: EXPERIMENTAL
Intervention: DBT plus SM
Number of subjects: 49462

Group type: COMPARATOR
Intervention: DM
Number of subjects: 49462
Study: 38051292

Group type: EXPERIMENTAL
Intervention: Unilocular cysts
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Septated cysts
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Cysts smaller than 3 cm
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Cysts larger than 6 cm
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Premenopausal status
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Older than age 70 years
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Not using hormone therapy
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 2638

Group type: EXPERIMENTAL
Intervention: Family history of ovarian cancer
Number of subjects: 2638
Study: 38051303

Group type: EXPERIMENTAL
Intervention: AK8 gene association with neurocognitive function changes
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: PTPRZ1, MUC16, TNRC6C-AS1 gene associations with anxiety
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: ZNF382 gene association with neurocognitive deficits in males
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: APOL2 and C6orf165 gene associations with anxiety
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: EXO5 gene association with depression
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: CYP2W1 and PCMTD1 gene associations with depression (modulatory effect of rare variants)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: ZNF382 gene association in combined cohorts (males)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: EXO5 gene association with depression in combined cohorts
Number of subjects: 229
Study: 38051326

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 459

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 459
Study: 38051327

Group type: EXPERIMENTAL
Intervention: Serial amnioinfusions of isotonic fluid before 26 weeks' gestation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Higher number of amnioinfusions
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gestational age greater than 32 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Higher birth weight
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Survival to hospital discharge while receiving peritoneal dialysis
Number of subjects: 21
Study: 38051328

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (capecitabine and oxaliplatin, XELOX regimen)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 650
Study: 38051631

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 16
Study: 38051647

Group type: EXPERIMENTAL
Intervention: CAS and tissue factor induced thrombin generation
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HRG levels
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Protein C concentration
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Antithrombin concentration
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Protein S concentration
Number of subjects: 117
Study: 38051678

Group type: EXPERIMENTAL
Intervention: Laser-assisted lenticule extraction (LALEX)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Femtosecond laser in situ keratomileusis (FS-LASIK)
Number of subjects: 108
Study: 38051699

Group type: EXPERIMENTAL
Intervention: Daily SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Weekly SMS reminders for TB patients and notifications to social supporters for 3 months, then triggered by late or missed dosing for 3 months.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no SMS).
Number of subjects: 63
Study: 38051700

Group type: EXPERIMENTAL
Intervention: Enhanced vitamin supplement
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Standard vitamin supplement (control)
Number of subjects: 1729
Study: 38051723

Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) combined with exercise (balance, strengthening, and mobility exercises guided by 15-minute action observation videos before a 45-minute exercise session)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise only (same exercises without action observation)
Number of subjects: 100
Study: 38051740

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus spp.)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 38051750

Group type: EXPERIMENTAL
Intervention: Peposertib 50-250 mg once daily plus capecitabine 825 mg/m2 twice daily and radiotherapy 5 days per week
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Peposertib 100 mg cohort
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Peposertib ≤150 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicities
Number of subjects: 19
Study: 38051993

Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38052037

Group type: EXPERIMENTAL
Intervention: VRD maintenance (bortezomib, lenalidomide, dexamethasone) for 3 years
Number of subjects: 177
Study: 38052038

Group type: EXPERIMENTAL
Intervention: TAG-AZA-VEN
Number of subjects: 56
Study: 38052042

Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg subcutaneously once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study: 38052059

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 0
Study: 38052073

Group type: EXPERIMENTAL
Intervention: Training Health Center Staff in Culturally Responsive Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 38052215

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 360
Study: 38052273

Group type: EXPERIMENTAL
Intervention: Bradycardia (BRADY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-CPR pulse pressure >20 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulseless electrical activity (PEA)
Number of subjects: 0
Study: 38052302

Group type: EXPERIMENTAL
Intervention: Protein-rich oral nutritional supplement for 4 weeks before TAVR with home-based supervised exercise sessions for 12 weeks after TAVR
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-of-care lifestyle education
Number of subjects: 200
Study: 38052376

Group type: EXPERIMENTAL
Intervention: Capacitation-IVM (CAPA-IVM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 46
Study: 38052709

Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 0
Study: 38052851

Group type: EXPERIMENTAL
Intervention: PEDF treatment of human skin fibroblast (HSF) cell lines with different concentrations and durations.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Psoriatic patients (no specific intervention mentioned, observational).
Number of subjects: 74
Study: 38052910

Group type: EXPERIMENTAL
Intervention: Divarasib plus cetuximab
Number of subjects: 29
Study: 38053101

Group type: EXPERIMENTAL
Intervention: Attitudes toward drugs measured by the Drug Attitude Inventory (DAI-10) at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline DAI-10 total score greater than -1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severity of the disease (CGI-s) and insight regarding the disease
Number of subjects: 0
Study: 38053114

Group type: EXPERIMENTAL
Intervention: High-intensity coaching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-intensity coaching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fall prevention alarm use
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fall rates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fall-related injuries
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Implementation outcomes
Number of subjects: 30
Study: 38053122

Group type: EXPERIMENTAL
Intervention: Group Brief Cognitive Behavioral Therapy (G-BCBT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy (DBT) Skills Group
Number of subjects: 136
Study: 38053197

Group type: EXPERIMENTAL
Intervention: Low-level light therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study: 38053196

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA) as add-on therapy to riluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 38053456

Group type: EXPERIMENTAL
Intervention: Hyperuricaemia
Number of subjects: 3628
Study: 38053515

Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily somatropin
Number of subjects: 0
Study: 38053534

Group type: EXPERIMENTAL
Intervention: KmAsthma self-management app
Number of subjects: 120
Study: 38053657

Group type: EXPERIMENTAL
Intervention: H-IGRT (hypofractionated 15 fractions/3 weeks image-guided radiation therapy)
Number of subjects: 123

Group type: COMPARATOR
Intervention: CRT (normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy)
Number of subjects: 123
Study: 38053659

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (25-40 Gy/5 Fx for cohort A; 15-30 Gy/5 Fx for cohort B), chemotherapy, toripalimab, and stereotactic ablative radiotherapy (SABR) for all metastatic lesions.
Number of subjects: 0
Study: 38053744

Group type: EXPERIMENTAL
Intervention: Metacognitive remediation (MCR) for 6 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Computerized cognitive remediation (CCR) for 6 months
Number of subjects: 22
Study: 38053913

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Serum biomarker panels
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Proposed new diagnostic criterion
Number of subjects: 114